Macro

Psychedelic treatments for mental health: Is there substance behind the hype?

Psychedelic treatments have been considered in the treatment of mental health since the 1950s, following Albert Hofmann’s development of lysergic…

AstraZeneca’s Evusheld fails to improve Covid outcomes in Phase III trial

The University of Minnesota’s Center for Infectious Disease Research & Policy (CIDRAP) has reported that AstraZeneca's monoclonal antibody combination drug,…

Osivax kicks off broad spectrum coronavirus vaccine trial

Osivax has kickstarted its Phase I clinical trial (NCT06128382) by vaccinating the first participant with its OVX033 sarbecovirus (coronavirus) vaccine…

Q4 2023 update: environmental sustainability related M&A activity in the pharmaceutical industry

Analysis of the key themes driving M&A activity reveals that environmental sustainability accounted for 6 pharmaceutical deals announced in Q4…

Q4 2023 update: COVID-19 related M&A activity in the pharmaceutical industry

Analysis of the key themes driving M&A activity reveals that COVID-19 accounted for 2 pharmaceutical deals announced in Q4 2023,…

Shionogi reports data from Phase III portion of Covid-19 drug trial

Shionogi has announced that ensitrelvir, its oral antiviral Covid-19 drug, has met primary and key secondary endpoints in the Phase…

AIM’s ampligen stumbles in Phase II trial

AIM ImmnunoTech has released topline results from a Phase II trial evaluating its Ampligen (rintatolimod) drug in people with post-Covid…

CSL and Arcturus’ Covid-19 booster found to prolong immunity

CSL and Arcturus Therapeutics have published follow-up analysis from a Phase III clinical trial indicating that ARCT-154, a self-amplifying messenger…

Q4 2023 update: mentions of social responsibility in pharmaceutical industry filings

The global pharmaceutical industry experienced a 35% drop in company filings mentions of social responsibility in Q4 2023 compared with…

Q4 2023 update: mentions of COVID-19 in pharmaceutical industry filings

The global pharmaceutical industry experienced a 69% drop in company filings mentions of COVID-19 in Q4 2023 compared with the…

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close